Skip to main content
Caplight Logo









Omniscope

Omniscope

Private
BarcelonaHealthcare & Life Scienceshttps://www.omniscope.ai/

Last Round

Early Funding

Feb 25, 2025

Total Funding Raised

$6.28M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Omniscope is a biotechnology company that develops an artificial intelligence-based platform to decode the immune system for diagnostic and therapeutic purposes.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical AI, Precision Medicine, Healthcare Analytics, Sports & Fitness

Business Model

B2B

Customer Profile

Subscription SaaS, Services & Consulting

AI Layer

Application

Keywords

immune decodinglongevitybiological aginghealthspanprecision medicinecellular avatarbiohackingimmune profilingsports medicinetechbiohealth optimizationdigital twinpredictive healthhealthcare analyticsSaaS

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Omniscope Comparables

Compare Omniscope with similar companies based on industry and business-model similarity.

Omniscope comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
LivePerson
76%
TruDiagnostic
72%
GlycanAge
66%

Omniscope Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingFeb 25, 2025
GrantJan 1, 2024
SeedJun 1, 2023
GrantSep 1, 2022
SeedOct 1, 2021

Omniscope Investors

Notable investors and investment history

Omniscope investors
InvestorRounds
European CommissionGrant
FoundersX VenturesEarly Funding, Seed
Buenavista Equity PartnersEarly Funding
Barça Innovation HubEarly Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 22, 2026

    Partnered with barnaclínic+ on AI-driven immune decoding for sports medicine.

  • Apr 22, 2026

    Launched AI-driven immune decoding technology with barnaclínic+.

Recent news

Latest coverage and updates

  • partners_withJun 23, 2026

    Omniscope Inc. partnered with SLK-Kliniken Heilbronn GmbH on Jun 23rd '26.

Omniscope Filings

Explore SEC and related filing metadata, where available.

Omniscope filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Omniscope's valuation, stock price, and market status.

Is Omniscope a public or private company?

Omniscope is a private company.

What is the current stock price of Omniscope?

Omniscope is a private company with no public stock price. No recent secondary market data is available.

How much is Omniscope worth (valuation)?

Valuation information for Omniscope is not publicly available.

Can I buy Omniscope stock?

Omniscope shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Omniscope's last funding round?

Omniscope's most recent funding round was Seed on February 25, 2025.

Who are the main investors in Omniscope?

Key investors in Omniscope include Buenavista Equity Partners.

Will Omniscope IPO soon?

No public IPO plans have been announced for Omniscope.

How can I track Omniscope secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Omniscope's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBarcelona
Employee Range23
Year Founded2020
Last FundingFeb 25, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?